Exact Sciences (NASDAQ:EXAS - Get Free Report) is expected to release its earnings data after the market closes on Wednesday, February 19th. Analysts expect Exact Sciences to post earnings of ($0.29) per share and revenue of $701.45 million for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.
Exact Sciences Price Performance
Exact Sciences stock traded down $1.28 during midday trading on Friday, reaching $49.31. 2,248,133 shares of the company were exchanged, compared to its average volume of 2,230,711. The company has a market capitalization of $9.13 billion, a price-to-earnings ratio of -42.14 and a beta of 1.24. The firm's 50-day simple moving average is $56.15 and its 200-day simple moving average is $60.18. Exact Sciences has a 1 year low of $40.62 and a 1 year high of $79.62. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12.
Analyst Upgrades and Downgrades
EXAS has been the subject of several recent analyst reports. Stifel Nicolaus lowered their price target on Exact Sciences from $82.00 to $67.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Jefferies Financial Group lifted their price target on Exact Sciences from $84.00 to $85.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. BTIG Research lifted their price target on Exact Sciences from $65.00 to $75.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. TD Cowen lifted their price target on Exact Sciences from $82.00 to $86.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. Finally, Piper Sandler lowered their price target on Exact Sciences from $85.00 to $75.00 and set an "overweight" rating for the company in a report on Monday, November 11th. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Exact Sciences has a consensus rating of "Moderate Buy" and an average target price of $72.76.
Check Out Our Latest Stock Report on EXAS
Exact Sciences Company Profile
(
Get Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Further Reading
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
